Clinical Trials Logo

Hepatic Ascites clinical trials

View clinical trials related to Hepatic Ascites.

Filter by:
  • None
  • Page 1

NCT ID: NCT05858853 Completed - Hepatic Ascites Clinical Trials

Phase II/III of Recombinant Human Serum Albumin

Start date: May 25, 2023
Phase: Phase 2/Phase 3
Study type: Interventional

This is a randomized, double-blind, position-controlled, parallel group phase II/III clinical study of recombinant human serum albumin (rHSA) in cirrhotic ascites patients.

NCT ID: NCT05249374 Completed - Hepatic Ascites Clinical Trials

Recombinant Human Serum Albumin in Patients With Liver Cirrhosis and Ascites Subjects

Start date: October 14, 2021
Phase: Phase 1
Study type: Interventional

This trial adopts a randomized, double-blind, positive drug-controlled, dose-escalated phase Ib clinical study evaluating the safety, tolerability, pharmacokinetic characteristics and preliminary effectiveness of recombinant human serum albumin in patients with liver cirrhosis and ascites subjects (both male and female) were screened and enrolled to the three dose levels of 10g, 20 g,and 30 g according to the principle of dose escalation, and 8 out of 12 subjects in each dose group One patient received the test drug, and 4 received a positive drug.

NCT ID: NCT05179265 Completed - Hepatic Ascites Clinical Trials

Recombinant Human Serum Albumin in Healthy Subjects

Start date: March 29, 2021
Phase: Phase 1
Study type: Interventional

This trial adopts a single-center, randomized, double-blind, dose-escalation, placebo-controlled design to evaluate the safety, tolerability, pharmacokinetics, and efficacy of a single administration of recombinant human serum albumin in healthy subjects Kinetics and anti-drug antibody characteristics. Qualified healthy subjects (both male and female) were screened and enrolled to the four dose levels of 2 g, 5 g, 10 g, and 20 g according to the principle of dose escalation, and 6 out of 8 subjects in each dose group One patient received the test drug, and two received a placebo.

NCT ID: NCT04785755 Completed - Hepatic Ascites Clinical Trials

Effects of Adding Hypertonic Saline Solutions and/or Etilefrine to Standard Diuretics Therapy in Hepatic Ascites

Start date: November 30, 2017
Phase: Phase 2
Study type: Interventional

This work aimed to evaluate and compare the impact of adding hypertonic saline solution (HSS) infusion and/or etilefrine to oral diuretics therapy on clinical outcomes, renal and systemic hemodynamics, metabolic and inflammatory pathways by estimating the changes in selected biological markers in cirrhotic patients with ascites. Also, the trial aims to assess the safety and tolerability of such treatment regimens.